Alys Pharmaceuticals is a biopharmaceutical company focused on developing immuno-dermatology treatments.
Alys Pharmaceuticals has raised $100.0M in total funding. The most recent round was Seed. The last funding was announced in February 2024.
Alys Pharmaceuticals's investors include Medicxi.
Alys Pharmaceuticals is headquartered in Boston, United States.
Alys Pharmaceuticals is a biopharmaceutical company focused on developing immuno-dermatology treatments.
Alys Pharmaceuticals is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alys Pharmaceuticals — Funding & Investors." VCBacked, February 12, 2024, https://www.vcbacked.co/company/alys-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2024). Alys Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/alys-pharmaceuticals
{{cite web |title=Alys Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/alys-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated